Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

• Main Authors: Paolo Gisondi (Author), Alice B. Gottlieb (Author), Boni Elewski (Author), Matthias Augustin (Author), Sandy McBride (Author), Tsen-Fang Tsai (Author), Christine de la Loge (Author), Frederik Fierens (Author), José M. López Pinto (Author), Nicola Tilt (Author), Mark Lebwohl (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumour necrosis factor biologic. Safety and efficacy data for CZP over 3 years have been previously reported. We report 3-year quality of life (QoL) outcomes for patients treated with CZP, pooled from two phase 3 trials. M...